Search PubMed⌕ Search

Biomedical subjects

T R Hoover

Publications and source records attributed to T R Hoover.

33 records · Page 2Linked to original sources
PubMed1989

Substrate reduction properties of dinitrogenase activated in vitro are dependent upon the presence of homocitrate or its analogues during iron-molybdenum cofactor synthesis.

(R)-2-Hydroxy-1,2,4-butanetricarboxylic acid [(R)-homocitrate] has been has been recently reported to be an integral constituent of the otherwise thought to be inorganic iron-molybdenum cofactor of dinitrogenase [Hoover, T.R., Imperial, J., Ludden, P.W., & Shah, V.K. (1989) Biochemistry 28,2768-2771]. Different organic acids can substitute for homocitrate in an in vitro system for iron-molybdenum cofactor synthesis and incorporation into dinitrogenase [Hoover, T.R., Imperial, J., Ludden, P.W., & Shah, V. K. (1988) Biochemistry 27, 3647-3652]. Dinitrogenase activated with homocitrate-FeMo-co was able to reduce dinitrogen, acetylene, and protons efficiently. Homoisocitrate and isocitrate dinitrogenases did not reduce dinitrogen or acetylene, but showed very high proton reduction activities. Citrate and citramalate dinitrogenases had very low dinitrogen reduction activities and intermediate acetylene and proton reduction activities. CO inhibited proton reduction in both these cases but not in the case of dinitrogenases activated with other homocitrate analogues. By use of these and other commercially available homocitrate analogues in the in vitro system, the structural features of the homocitrate molecule absolutely required for the synthesis of a catalytically competent iron-molybdenum cofactor were determined to be the hydroxyl group, the 1- and 2-carboxyl groups, and the R configuration of the chiral center. The stringency of the structural requirements was dependent on the nitrogenase substrate used for the assay, with dinitrogen having the most stringent requirements followed by acetylene and protons.

Bacteria↗
PubMed1989

Homocitrate is a component of the iron-molybdenum cofactor of nitrogenase.

When apodinitrogenase (lacking FeMo-co) was activated with FeMo-co synthesized in vitro in the presence of 3H-labeled homocitrate, label was incorporated into dinitrogenase. The physical association of the label with FeMo-co was demonstrated by reisolation and purification of the cofactor from dinitrogenase. The presence of homocitrate in FeMo-co was established by NMR analysis of the organic acid extracted from dinitrogenase. Quantitation of homocitrate in dinitrogenase showed it to be present at a 1:1 ratio with molybdenum.

Chromatography, DEAE-Cellulose↗
PubMed1988

Dinitrogenase with altered substrate specificity results from the use of homocitrate analogues for in vitro synthesis of the iron-molybdenum cofactor.

The in vitro synthesis of the iron-molybdenum cofactor (FeMo-co) of nitrogenase requires homocitrate (2-hydroxy-1,2,4-butanetricarboxylic acid). Homocitrate is apparently synthesized by the nifV gene product. In the absence of homocitrate, no FeMo-co is formed in vitro, as determined from coupled C2H2 reduction assays and the lack of 99Mo label incorporation into apodinitrogenase. Several organic acids were tested for their ability to replace homocitrate in the FeMo-co synthesis system. With appropriate homocitrate analogues, aberrant forms of FeMo-co are synthesized that exhibit altered substrate specificity and inhibitor susceptibility. Homoisocitrate (1-hydroxy-1,2,4-butanetricarboxylic acid) and 2-oxoglutarate facilitated the incorporation of 99Mo into apodinitrogenase in the FeMo-co synthesis system, yielding a dinitrogenase that effectively catalyzed the reduction of protons but not C2H2 or N2. Citrate also promoted the incorporation of 99Mo into apodinitrogenase, and the resulting holodinitrogenase reduced protons and C2H2 effectively but not N2. In addition, proton reduction from this enzyme was inhibited by CO. The properties of the homodinitrogenase formed in the presence of citrate were reminiscent of those of the Klebsiella pneumoniae NifV- dinitrogenase. We also observed low rates of HD formation from NifV- dinitrogenase compared to those from the wild-type enzyme. No HD formation was observed with the dinitrogenase activated in vitro in the presence of citrate. We propose that in vivo NifV- mutants utilize citrate for FeMo-co synthesis.

Enzyme Activation↗
PubMed1988

Homocitrate cures the NifV- phenotype in Klebsiella pneumoniae.

Dinitrogenase was isolated from a culture of a Klebsiella pneumoniae NifV- strain derepressed for nitrogenase in the presence of homocitrate. The enzyme isolated from this culture was identical to the wild-type dinitrogenase. These data provide in vivo evidence that the absence of homocitrate is responsible for the NifV- phenotype.

Dinitrogenase Reductase↗
PubMed1988

Biosynthesis of the iron-molybdenum cofactor of nitrogenase.

The iron-molybdenum cofactor (FeMo-co) of nitrogenase is a Mo-Fe-S cluster that has been proposed as the site of substrate reduction for the nitrogenase enzyme complex. Biosynthesis of FeMo-co in Klebsiella pneumoniae requires at least six nif (nitrogen fixation) gene products. One of the nif genes, nifV, apparently encodes a homocitrate synthase. The synthesis and accumulation of homocitrate [(R)-2-hydroxy-1,2,4-butanetricarboxylic acid] in K.pneumoniae is correlated to the presence of a functional nifV gene. K.pneumoniae strains with mutations in nifV synthesize and accumulate an aberrant form of FeMo-co. Nitrogenase from NifV- mutants is capable of reducing some of the substrates of nitrogenase effectively (e.g. acetylene), but reduces N2 poorly. With the aid of an in vitro FeMo-co synthesis system, it recently has been established that homocitrate is an endogenous component of FeMo-co. Substitution of homocitrate with other carboxylic acids results in the formation of aberrant forms of FeMo-co with altered substrate reduction capability.

Chemical Phenomena↗
PubMed1986

nifV-dependent, low-molecular-weight factor required for in vitro synthesis of iron-molybdenum cofactor of nitrogenase.

The molybdate- and ATP-dependent in vitro synthesis of the iron-molybdenum cofactor of nitrogenase requires a low-molecular-weight factor. The factor is present in extracts of nitrogen fixation-derepressed cultures of Klebsiella pneumoniae and Azotobacter vinelandii, but not in extracts of repressed cultures of these bacteria. Analysis of K. pneumoniae Nif mutants has indicated that the nifV gene product is the only nif protein (besides nifA) necessary for the synthesis and accumulation of the factor. The factor is stable to oxygen, temperatures below 120 degrees C, and extremely acidic and basic conditions. The activity of the factor was completely destroyed by dry ashing or digestion with sulfuric acid. The factor has been partially purified by filtration through an Amicon PM-10 DIAFLO membrane and chromatography on DEAE-cellulose, hydroxylapatite, silica gel, and Sephadex G-25.

Azotobacter↗
PubMed1984

Derepression of nitrogenase by addition of malate to cultures of Rhodospirillum rubrum grown with glutamate as the carbon and nitrogen source.

Rhodospirillum rubrum grown in continuous culture with glutamate as the sole fixed C and N source produced no nitrogenase, and the cultures were characterized by high extracellular ammonium concentrations. Addition of organic acids derepressed nitrogenase. Glutamate dehydrogenase, glutamine synthetase, glutamate synthase, malate dehydrogenase, nitrogenase, and ammonium were assayed before and after malate addition.

Ammonia↗
PubMed1979

Effect of portal versus jugular methionine infusion on circulating amino acids and nitrogen metabolism in sheep.

A double cross-over experiment with 2 rumen-, bilateral jugular vein-, and portal vein-cannulated sheep was performed to determine the influence of route of infusion of methionine on nitrogen balance and blood amino acids. Nutrients were provided solely by intravenous (glucose, amino acids, water soluble vitamins) and intraruminal (VFA, minerals) infusion. Treatments consisted of the infusion of methionine plus serine via either the jugular vein (J) or portal vein (P). The respective order of treatments for the sheep were J, P, J, P and P, J, P, J. Urinary nitrogen was lower and nitrogen balance was greater when methionine was infused intrajugularly. No differences in plasma or blood urea nitrogen were noted. Plasma amino acid (PAA) concentrations showed no significant differences due to treatment. However, whole blood amino acid (BAA) concentrations revealed significantly greater levels of methionine when methionine was administered via the jugular vein. Expression of PAA as percentages of the total resulted in no treatment effects, while percentage expression of BAA showed that methionine was greater and phenylalanine was lower during intrajugular methionine infusion. The central and peripheral methionine infusion routes appeared to influence slightly the subsequent utilization of methionine as determined by effects on BAA levels of methionine. It was demonstrated that results from analysis of circulating amino acids may differ according to whether plasma or whole blood samples are used, and whether the data are expressed as concentrations or proportions.

Amino Acids↗
PubMed1976

Twelfth rib resection as an approach for portal vein cannulation in sheep.

A surgical technique involving resection of the twelfth rib was used to insert silastic cannulas into the portal veins of three sheep to study amino acid metabolism. Good exposure to the vein was achieved by this method although it required positive ventilation due to the penetration of the thoracic cavity. All cannulas were buried subcutaneously and exteriorized near the dorsal midline. This facilitated continuous infusion into the portal cannula without disturbing cannula placement.

Amino Acids↗
PubMed1975

Surgical and anatomic study of calving paralysis.

Dissections of the bovine pelvic inlet region were made to determine which nerves were vulnerable to fetal-induced traumatic damage. Surgical sections of the obturator nerves and the lumbar roots of the sciatic (ischiatic) nerves were done to determine a possible cause of calving paralysis. Only 1 of 11 cattle in which bilateral obturator nerve section was done was unable to stand after the operation, and in this individual, secondary stifle injuries were found on necropsy. Subsequent surgical operations were performed on some of these cattle in order to section the lumbar root of the sciatic nerve. Of 6 cattle prepared, 2 were unable to rise after surgery and another 2 became "downer" cattle after 30 to 45 minutes of forces exercise. Also, some of these cattle were very ataxic and had intermittent fetlock flexion.

Animals↗
PubMed1975

Anesthesia of bulls undergoing surgical manipulation of the vas deferentia.

Twelve bulls ranging from 341 to 545 kilograms in body mass were successfully anesthetized for either vasectomy or prosthetic vas deferens implantation with a combination of thiopental sodium, glyceryl guaiacolate, nitrous oxide, halothane and oxygen. Duration of anesthetic administration was 119.2 plus or minus 24.2 (S.D.) minutes. Righting reflexes returned 15.0 plus or minus 8.0 minutes after cessation of anesthetic administration and the bulls were capable of standing within 46.6 plus or minus 17.8 minutes. Interpretations of pulse rate, respiratory rate and eye reflexes were related to anesthetic depth and maintenance. A control mean respiratory frequency of 28.8 plus or minus 3.6 per minute compared to minimum and maximum frequencies of 26.8 plus or minus 5.1 and 37.6 plus or minus 6.3, respectively, during anesthetic maintenance. A control mean pulse frequency of 91.6 plus or minus 15.9 per minute compared to minimum and maximum frequencies of 84.8 plus or minus 13 and 102.3 plus or minus 13.4, respectively, during maintenance of anesthesia. Methods for avoiding complications related to anesthetic induction, maintenance and emergence were described. Specific pharmacological aspects of atropine, halothane and nitrous oxide were emphasized in light of their application to ruminant anesthesia.

Anesthesia, Inhalation↗
PubMedDate not supplied

Identification of the V factor needed for synthesis of the iron-molybdenum cofactor of nitrogenase as homocitrate.

Nitrogenase catalyses the ATP-dependent reduction of N2 to NH3, and is composed of two proteins, dinitrogenase (MoFe protein or component I) and dinitrogenase reductase (Fe protein or component II). Dinitrogenase contains a unique prosthetic group (iron-molybdenum cofactor, FeMoco) comprised of Fe, Mo and S, which has been proposed as the site of N2 reduction. Biochemical and genetic studies of Nif- (nitrogen fixation) mutants of Klebsiella pneumoniae which are defective in nitrogen fixation, have shown that the nifB, nifQ, nifN, nifE and nifV genes are required for the biosynthesis of FeMo-co. Recently, a system for in vitro synthesis of FeMoco was described. The assay requires at least the nifB, nifN and nifE gene products, and a low-molecular-weight factor (V factor) produced in the presence of the nifV gene product. We have used this system to study FeMoco biosynthesis. We report here the isolation of V factor and identify it as homocitric acid ([R]2-hydroxy-1,2,4-butanetricarboxylic acid).

Ferredoxins↗